All the Therapeutic System Drugs
5-HT3 Antagonist, Selective Antagonist of NK1 Receptors. Netupitant 300 mg, Palonosetron (hydrochloride) 0.5 mg. CAP.: 1. One 300 mg / 0.5 mg cap. should be administered approx. one h. prior to the start of each chemother. cycle. The recommend. oral dexamethasone dose should be reduced by approx. 50 % when co-admin. with this formul.
Preven.of acute & delayed nausea and vomit. assoc. with init. and repeat courses of cancer chemoth., includ., but not limited to, highly emetogenic chemother.
C/I: Hypersens., preg.
Cannabinoids. THC 0.3, 0.9, 1.5, 3, 4.5 mg/drop, CBD 0.6, 0.9, 3, 4.5, 6 mg/drop. *This product requires a license for medical cannabis.
BOTTLE. (sublingual drop.): 10gr (330 drops). Dosage should be adjust. individual.
The Israel MOH has outlined in Guidance 106 the 12 indicat. for which med. cannabis is indicated. Accord. to this guidance, the 11 indicat. for this product are:
Chemother-induc. nausea and vomit. (CINV)/ chemother induc. pain.
Metastat. cancer pain.
Spastic. of MS.
Pain in Parkinson's dis.
Cachexia in AIDS.
Recalcitrant epilep. in adult. (Note: Accord. to Guidance 106, med. cannab. is also indic. for recalcitrant epilep. in ped. pts. but this is not an indicat. for this product)
Palliative care for termin. ill pts.
Post- traum. stress disord.
In general, the use of med. cannabis is indicated in pts. who have adequate. tried and failed convent. ther.
Please refer to Guidance 106 for details.
In addition, for an individ. pt. with a clinical. signific. med. condit. that cannot be adequate. managed by convent. ther. and which is not includ. as one of the 12 approved indicat. (eg autism, fibromyalgia), the physician can appeal to the MOH Committee for Med. Cannabis to ask for approval on an individ. exception. basis.
C/I: Prior, current/ family history (1st degr. relative) of psychos. or schizophr. or schizoaffective disord., a hist. of addict. or substance abuse (include. cannabis use disord.or addict. to alcohol), use in preg.or lact., use in pts. <18 yrs. old, bipol.disord., hypersens. to cannabis, coconut oil, palm kernel oil.
In pts. with hepat. cancer, it is recommend. not to use med. cannab. that contains THC.
Substance P/NK1 Antagonist. Aprepitant 80 mg, 125 mg. CAPS: 1 x 125 mg + 2 x 80 mg. To be
used in comb. with 5HT-3 antagonist
and corticosteroid. Day 1: 125 mg 1 hr.
prior to chemother. Day 2 and 3: 80 mg
1 x dly in morn. May be taken with/out
In comb. with other anti-emet. agents
for prevent. acute/delayed nausea/
vomit. assoc. with initial/repeat. courses
highly emetogen. cancer chemother.,
incl. high dose cisplatin.
C/I: Hypersens. See lit.
Antidopaminergic. Domperidone 10 mg. F.C. TABS: 30 x 10 mg.
Adults (12 yrs and older & wt. ≥35 kg)
one 10 mg tab. up to 3/d, max. dose of
30 mg/d. Neonates, infants, children (less than 12 yrs) and adolesc. wt. < 35
kg: F.C. Tabs. are unsuit. for use.
For the relief of the sympt. of nausea and
C/I: Hypersens.; Prolactin-releasing
pituitary tumor (prolactinoma);
when stimul. of gastric mot. could be
harmful, e.g. GI hemorrh., mechan.
obstruct./ perfor.; mod.-sev. hep. impair.;
existing prolongation of cardiac cond.
interv., particularly QTc, pts. with sign.
electrolyte disturb. or underl. cardiac dis.
e.g. CHF; co-administr. with QT-prolong.
drugs; co-administr. with potent CYP3A4
5-HT3 Antagonist. Ondansetron (as HCl dihydrate) 2 mg/ml. AMPS: 1, 5, 10, 50 x 2 ml, 4ml. Depends on indica. and age. See lit.
Adults: tmt of nausea and vomit. induced by cytotoxic chemother. and radiother.,prevent. and tmt of post-operative nausea and vomit.(PONV). Child: tmt of chemotherapy-induced nausea and vomit. (CINV) in children aged ≥6 months and for prevent. and tmt of PONV in children aged ≥ 1month.
C/I: Hypersens., concom. use with apomorphine.
5-HT3 Antagonist. Ondansetron 4 mg, 8 mg. F.C.TABS.: 3, 4, 6, 7, 10, 14, 15, 20, 28, 30,
40, 49, 50, 60, 90, 100, 200, 300, 500.
8 mg ×2/d.
Manag. of nausea and vomit. induced by
cytotoxic chemother. and radiother.
Preven. and tmt. of postoperat. nausea
and vomit. in adults.
C/I: Hypersens. Concom. use with